OSA对CPAP撤除期间缺氧与炎症标志物的影响:三项随机对照试验的进一步证据
本研究基于三项随机对照试验,纳入109例已长期接受CPAP治疗的OSA患者,随机分为继续治疗CPAP或假CPAP(撤除CPAP)2周。结果显示假CPAP组OSA复发(ODI组间差36.0/h),但ADM水平显著降低(-26.0 pg/mL),而endocan、ET-1、resistin和VEGF无变化。提示OSA的血管效应可能部分通过ADM减少介导。
要点
- CPAP撤除2周导致OSA复发,ODI组间差36.0/h(95%CI 29.9-42.2)。
- OSA复发伴随ADM水平降低26.0 pg/mL(95%CI -47.8至-4.3),而非预期升高。
- endocan、ET-1、resistin和VEGF在CPAP撤除后无显著变化。
核心结论
- CPAP撤除导致OSA复发,但意外发现血管扩张剂ADM显著降低,而非缺氧诱导标志物、内皮功能标志物或resistin的预期升高。
- OSA的血管效应可能由其他机制介导,部分或通过ADM减少实现。
研究设计与样本
- 三项随机对照试验,在两个中心进行。
- 纳入已接受并依从CPAP治疗>1年的OSA患者109例,随机分为继续治疗CPAP(n=54)或假CPAP(n=55)2周。
- 在基线和14天测量血液标志物,分析假CPAP与治疗CPAP之间的治疗效应。
主要发现
- 假CPAP与OSA复发相关:ODI组间差36.0/h(95%CI 29.9-42.2,P<0.001)。
- 假CPAP与14天时ADM水平降低相关:-26.0 pg/mL(95%CI -47.8至-4.3,P=0.02), compared to therapeutic CPAP。
- OSA复发与endocan、ET-1、resistin或VEGF的变化无关。
临床怎么用
- 对于长期CPAP治疗的OSA患者,短期撤除CPAP可导致OSA复发和ADM降低,提示ADM可能参与OSA相关血管效应。
- 临床监测OSA心血管风险时,除传统缺氧和炎症标志物外,可考虑ADM的潜在价值。
局限性
- 研究仅观察2周,长期影响未知。
- 样本量有限,可能影响对其他标志物变化的检测效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Obstructive sleep apnoea (OSA) is associated with cardiovascular disease. Intermittent hypoxia, endothelial dysfunction and adipose tissue-mediated inflammation have all been linked to cardiovascular disease in OSA. We therefore explored the effect of OSA on relevant associated blood markers: adrenomedullin (ADM), endocan, endothelin-1 (ET-1), resistin and vascular endothelial growth factor (VEGF). METHODS: Patients with OSA, established on and compliant with continuous positive airways pressure (CPAP) therapy for >1 year were included from three randomized controlled trials, conducted at two centres. Patients were randomized to either continued therapeutic CPAP or sham CPAP (CPAP withdrawal) for 2 weeks. Blood markers were measured at baseline and at 14 days and the treatment effect between sham CPAP and therapeutic CPAP was analysed. RESULTS: A total of 109 patients were studied (therapeutic CPAP n = 54, sham CPAP n = 55). Sham CPAP was associated with a return of OSA (between-group difference in oxygen desaturation index (ODI) 36.0/h, 95% CI 29.9-42.2, P < 0.001). Sham CPAP was associated with a reduction in ADM levels at 14 days (-26.0 pg/mL, 95% CI -47.8 to -4.3, P = 0.02), compared to therapeutic CPAP. Return of OSA was not associated with changes in endocan, ET-1, resistin or VEGF. CONCLUSION: Whilst CPAP withdrawal was associated with return of OSA, it was associated with an unexpected significant reduction in the vasodilator ADM and not with expected increases in hypoxia-induced markers, markers of endothelial function or resistin. We propose that the vascular effects occurring in OSA may be brought about by other mechanisms, perhaps partly through a reduction in ADM.
引用
- Turnbull CD, Rossi VA, Santer P, et al. Effect of OSA on hypoxic and inflammatory markers during CPAP withdrawal: Further evidence from three randomized control trials. Respirology. 2016. PMID: 27860068. doi:10.1111/resp.12946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。